Rhoda M. Alani, MD


Herbert Mescon Professor and Chair, Department of Dermatology

Boston University School of Medicine

Dermatologist-in-Chief Boston Medical Center

Administrative Office

Boston University, Department of Dermatology

609 Albany Street, J-507
Boston, MA 02118
Office: 617-638-5517
Fax: 617-638-5543



1991 MD University of Michigan Medical School, Ann Arbor, MI
1991-1992 Internship Internal Medicine, Yale Univesity School of Medicine
1992-1995 Residency Harvard Medical School, Masschusetts General Hospital, Boston, MA
1994-1997 Postdoctoral Fellowship Harvard Medical School, Boston, MA

Clinical Specialties and Research Interests

Clinical: Melanoma, Pigmented Lesions

Research: Molecular Determinants of Melanoma Development and Progression, Melanoma Biomarkers, Novel Therapies for Melanoma, Epigenetics and Cancer, Imaging Tools for Melanoma and Pigmented Lesions

For additional information on Dr. Alani’s Research Program, please click here.


Rhoda M. Alani, MD is the Herbert Mescon Professor and Chair of Dermatology at Boston University School of Medicine and Boston Medical Center. She received her MD degree with Honors and Distinction in Research from the University of Michigan and completed her internship in internal medicine at Yale-New Haven Hospital and a residency in dermatology at Harvard Medical School. From 1999-2009 Dr. Alani was the Director of the Laboratory of Cutaneous Oncology and Director of the Melanoma and Pigmented Lesion Clinics in Dermatology at Johns Hopkins. Dr. Alani’s research focus is in understanding the molecular basis of melanoma development and progression with the aim of translating her laboratory findings to better prevention, detection, diagnosis, and treatment of melanoma. Dr. Alani is a member of Phi Beta Kappa and Alpha Omega Alpha Honor Societies, the American Academy of Dermatology, the Society for Investigative Dermatology, the American Association for Cancer Research and was elected to the American Society for Clinical Investigation in 2005. She is the author of numerous scientific publications and is the owner of several US patents related to melanoma biomarkers, novel melanoma therapies, and imaging systems for improved melanoma detection

Selected Publications

  1. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, Crump NT, Hazzalin CA, Liszczak G, Yuan H, Larocca C, Saldanha SA, Abagyan R, Sun Y, Meyers DJ, Marmorstein R, Mahadevan LC, Alani RM, Cole PA. Chem Biol. 2010 May 28;17(5):471-82.PMID: 20534345
  2. Melanoma biomarkers: current status and vision for the future. Larson AR, Konat E, Alani RM. Nat Clin Pract Oncol. 2009 Feb;6(2):105-17. Epub 2008 Dec 23. PMID: 19107110
  3. Toward a molecular classification of melanoma. Fecher LA, Cummings SD, Keefe MJ, Alani RM. J Clin Oncol. 2007 Apr 20;25(12):1606-20. PMID: 17443002
  4. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. Ryu B, Kim DS, Deluca AM, Alani RM. PLoS One. 2007 Jul 4;2(7):e594.PMID: 17611626
  5. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Sikder H, Huso DL, Zhang H, Wang B, Ryu B, Hwang ST, Powell JD, Alani RM. Cancer Cell. 2003 Oct;4(4):291-9.PMID: 14585356
  6. Id proteins in cell growth and tumorigenesis. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM. Cancer Cell. 2003 Jun;3(6):525-30.  PMID: 12842081
  7. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM. Cancer Cell. 2002 Dec;2(6):473-83.PMID: 12498716